Menumenu
  • Home
  • Oncology Publications

Oncology Publications

Oncology Publications

  • No decreased risk of gastrointestinal cancers in users of metformin in The Netherlands; a time-varying analysis of metformin exposure.Abstract

    Previous studies on metformin use and gastrointestinal (GI) cancer risk have yielded inconclusive results on metformin’s chemoprotective effects. We aimed to evaluate GI cancer risk in users of metformin in The Netherlands using a time-varying apprach in a large population-based database. A cohort study was performed using the NCR-PHARMO database

    deJong RG, Burden AM, deKort S, van Herk-Sukel M, Vissers PA, Janssen PK, Haak HR, Masclee AA, deVries F, Janssen-Heijnen ML. Cancer Prev Res (Phila). 2017 Mar 08;
  • Chemotherapy for ovarian cancer in the Netherlands: a population-based study on treatment patterns and outcomes.Abstract

    Information on treatment patterns for ovarian cancer (OC) is limited. The aim of this study was to describe current patterns of chemotherapy and other systemic treatments for OC in the Netherlands and evaluate survival outcomes following subsequentlines of treatment. Data from the Eindhoven Cancer Registry, including on newly diagnosed cancer patients, were linked to the PHARMO Database Network, including information on in- and out-patient drug use

    Houben E, van Haalen HG, Sparreboom W, Overbeek JA, Ezendam NP, Pijnenborg JM, Severens JL, van Herk-Sukel MP. Med Oncol. 2017 Apr; 34 50.
  • No association between metformin use and survival in patients with pancreatic cancer: An observational cohort study.Abstract

    Several studies have suggested an association between use of metformin and an increased overall survival in patients diagnosed with pancreatic cancer, however with several important methodological limitations. The aim of the study was to assess theassociation between overall survival, pancreatic cancer, and metformin use

    Frouws MA, Mulder BG, Bastiaannet E, Zander s MM, van Herk-Sukel MP, deLeede EM, Bonsing BA, Mieog JS, VandeVelde CJ, Liefers GJ. Medicine (Baltimore). 2017 Mar; 96 e6229.
  • Effect of low-dose aspirin use on survival of patients with gastrointestinal malignancies; an observational study.Abstract

    BACKGROUND: Previous studies suggested a relationship between aspirin use and mortality reduction. The mechanism for the effect of aspirin on cancer outcomes remains unclear. The aim of this study was to evaluate aspirin use and survival in patientwith gastrointestinal tract cancer. METHODS: Patients with gastrointestinal tract cancer diagnosed between 1998 and 2011 were included

    Frouws MA, Bastiaannet E, Langley RE, Chia WK, van Herk-Sukel MP, Lemmens VE, Putter H, Hartgrink HH, Bonsing BA, Vande Velde CJ, Portielje JE, Liefers GJ. Br J Cancer. 2017 Jan; 116 405-413.
  • The Influence of BRAF and KRAS Mutation Status on the Association between Aspirin Use and Survival after Colon Cancer Diagnosis.Abstract

    BACKGROUND: Use of aspirin after diagnosis of colon cancer has been associated with improved survival. Identification of cancer subtypes that respond to aspirin treatment may help develop personalized treatment regimens. The aim of this study was tinvestigate the influence of BRAF and KRAS mutation status on the association between aspirin use and overall survival after colon cancer diagnosis

    Frouws MA, Reimers MS, Swets M, Bastiaannet E, Prinse B, van Eijk R, Lemmens VE, van Herk-Sukel MP, van Wezel T, Kuppen PJ, Morreau H, van de Velde CJ, Liefers GJ. PLoS One. 2017 12 e0170775.
  • Propranolol and survival from breast cancer: a pooled analysis of European breast cancer cohorts.Abstract

    BACKGROUND: Preclinical studies have demonstrated that propranolol inhibits several pathways involved in breast cancer progression and metastasis. We investigated whether breast cancer patients who used propranolol, or other non-selective beta-blocers, had reduced breast cancer-specific or all-cause mortality in eight European cohorts

    Cardwell CR, Pottegard A, Vaes E, Garmo H, Murray LJ, Brown C, Vissers PA, O'Rorke M, Visvan athan K, Cronin-Fenton D, DeSchutter H, Lambe M, Powe DG, van Herk-Sukel MP, Gavin A, Friis S, Sharp L, Bennett K. Breast Cancer Res. 2016 Dec 01; 18 119.
  • Drug dispensings among elderly in the year before colon cancer diagnosis versus matched cancer-free controls.Abstract

    WHAT IS KNOWN AND OBJECTIVE: The concomitant use of multiple drugs is common among the general population of elderly. The aim of this study was to provide an overview of which drugs are dispensed to elderly in the year before colon cancer diagnosisand to compare this with cancer-free controls. METHODS: Data from the Eindhoven Cancer Registry were linked to the PHARMO Database Network

    van Erning FN, Zander s MM, Kuiper JG, van Herk-Sukel MP, Maas HA, Vingerhoets RW, Zimmerman DD, deFeyter EP, van dePoll ME, Lemmens VE. J Clin Pharm Ther. 2016 Oct; 41 538-45.
  • The effect of aspirin and nonsteroidal anti-inflammatory drug use after diagnosis on survival of oesophageal cancer patients.Abstract

    BACKGROUND: Aspirin use has been shown to lower incidence and mortality in cancer patients. The aim of this population-based study was to determine the effect of postdiagnosis low-dose aspirin use on survival of patients with oesophageal cancer. MEHODS: Patients with oesophageal cancer (1998-2010) were selected from the Eindhoven Cancer Registry and linked with outpatient pharmacy data regarding aspirin and nonsteroidal anti-inflammatory drugs (NSAIDs)

    van Staalduinen J, Frouws M, Reimers M, Bastiaannet E, van Herk-Sukel MP, Lemmens V, de Steur WO, Hartgrink HH, van de Velde CJ, Liefers GJ. Br J Cancer. 2016 Apr 26; 114 1053-9.
  • Pioglitazone use and risk of bladder cancer in patients with type 2 diabetes: retrospective cohort study using datasets from four European countries.Abstract

    OBJECTIVE: To evaluate the association between pioglitazone use and bladder cancer risk in patients with type 2 diabetes. DESIGN: Retrospective cohort study using propensity score matched cohorts. SETTINGS: Healthcare databases from Finland, the Neherlands, Sweden, and the United Kingdom. Data comprised country specific datasets of linked records on prescriptions, hospitals, general practitioners, cancer, and deaths

    Korhonen P, Heintjes EM, Williams R, Hoti F, Christopher S, Majak M, Kool-Houweling L, Strongman H, Linder M, Dolin P, Bahmanyar S. BMJ. 2016 354 i3903.
  • Are metformin, statin and aspirin use still associated with overall mortality among colorectal cancer patients with diabetes if adjusted for one another?.Abstract

    BACKGROUND: Metformin, statin and aspirin use seem associated with decreased mortality in cancer patients, though, without adjusting for one another. Independent associations of these drugs with overall mortality after colorectal cancer (CRC) diagnsis within glucose-lowering drugs (GLDs) users were assessed

    Zander s MM, van Herk-Sukel MP, Vissers PA, Herings RM, Haak HR, van dePoll-Franse LV. Br J Cancer. 2015 Jul 28; 113 403-10.